Brief: Pediapharm announces global exclusive licensing agreement for Relaxa(R)

Medexus Pharmaceuticals

19/09/2016 12:31

Sept 19 (Reuters) - Pediapharm Inc  PDP.V  
    * Pediapharm announces global exclusive licensing agreement 
for Relaxa(R), an established Canadian product with existing 
revenues 
    * Pediapharm will pay licensor royalties based on annual net 
sales of product 
    * Under terms of licensing agreement, co has right to 
acquire Relaxa(R) at any time until 7th anniversary of effective 
date of licensing agreement 
    * Under terms of licensing agreement, co has exclusive right 
to manufacture, promote, market, sell and distribute Relaxa(R) 
globally 
    * Price payable for Relaxa(R) during such term shall be 5 
million dollars plus a 2% royalty on annual net sales of product 
up to $1.5 million 
 
Source text for Eikon:  ID:nCCNc4GW2n  
Further company coverage:  PDP.V  
 
 ((Bangalore.newsroom@thomsonreuters.com;))